29 / 33
Page 83
Notes:
conferenceseries
.com
Volume 7, Issue 6 (Suppl)
J Alzheimers Dis Parkinsonism, an open access journal
ISSN: 2161-0460
Dementia 2017
October 16-18, 2017
ALZHEIMER’S DISEASE & DEMENTIA
October 16-18, 2017 | Rome, Italy
9
th
International Conference on
J Alzheimers Dis Parkinsonism 2017, 7:6(Suppl)
DOI: 10.4172/2161-0460-C1-034
Multi-target-directed ligands inhibition of acetylcholinesterase, amyloid aggregation and its
significance in Alzheimer’s disease treatment
Seta Tosonyan, Shanlin Fu, Ronald Shimmon
and
Susan Shimmon
University of technology Sydney, Australia
A
treatment to the Alzheimer’s disease (AD) consists of inhibition of the Acetylcholinesterase, which is responsible for the
acetylcholine control in the synapses.Anewclass ofmulti-target-directed ligands (MTDLs) basedona1,10-phenanthroline-
5,6-dione derivatives were tested in vitro against acetylcholinesterase (AChE) these compounds inhibit AChE-induced anti-
amyloid (Aβ) aggregation. 1,10-phenanthroline5,6-dione can act as a lead molecule for developing drug(s) against AD disease
with dual functions namely. The in vitro evaluation of the prepared compounds were tested by using Ellman’s colorimetric
method in 96-welled microplates some of them showed lower IC50 values on inhibiting the AChE and the IC50 value 6E-6-
[(2-hydroxyphenyl) imino]-1,10-phenanthrolin-5(6H)-one was 53 mM. This study provided beneficial information for further
development of resveratrol derivatives as multitarget-directed agents for AD therapy.
seta.a.tosonyan@student.uts.edu.au